Radiation Oncology

Nuclear Medicine

Questions discussed in this category

For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?

FDG PET, Axumin PET, Bone scan? Or just proceed with salvage ADT/RT?

4 Answers available

How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?

With the recent publication of PSMAfore, what are your current criteria for offering Lu-177 therapy?

1 Answer available

What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?

1 Answer available

How do you manage dry eye related to Pluvicto Lu-177?

2 Answers available

Would you offer prostate specific PET imaging (e.g. Axumin or PSMA PET) in a post-RT prostate cancer patient that has a rising PSA that has not yet met failure criteria?

4 Answers available

Are you using prostate PET imaging for any newly-diagnosed prostate cancers?

For example, are PET Axumin or PSMA studies being ordered in the upfront setting?

1 Answer available

Would you consider 177Lu-Dotatate (Lutathera) in patients with midgut neuroendocrine carcinoma after treatment with a somatostatin analog but with Ki67 >20%?

This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are withi...

2 Answers available

For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

2 Answers available

Would you use a PSMA test obtained as part of a clinical trial to alter your treatment management?

Does PSMA have enough data to use to guide therapy, even if the result is obtained as part of a clinical trial? Would you change your hormonal recomme...

1 Answer available

Are prostate PET scans (axumin, PSMA, etc.) still useful for patients on androgen suppression therapy?

Is there any information on how ADT affects the test operating characteristics?

4 Answers available

Papers discussed in this category

Radiother Oncol, 2022 Feb 18

Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage.

Practical radiation oncology, 2018

Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-01

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

Nucl Med Mol Imaging, 2016 Aug 06

Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.

Int. J. Oncol., 2012 Oct 04

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells.

Urology, 1996-08

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Eur. J. Nucl. Med. Mol. Imaging, 2017 Apr 14

PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

The New England journal of medicine, 2011-07-14

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Lancet, 2016 Mar 19

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

International journal of radiation oncology, biology, physics, 2017-06-01

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Lancet Oncol., 2018 Dec 19

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

Radiother Oncol, 2020 Apr 01

Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.

J Clin Oncol, 2021 Jan 26

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.

Int J Radiat Oncol Biol Phys, 2021 Sep 01

Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.

The New England journal of medicine, 2017-07-27

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

JAMA Oncol, 2021 Feb 18

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Endocr Relat Cancer,

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.

J Nucl Med, 2018 Aug 16

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.

Eur J Nucl Med Mol Imaging, 2017 Sep 12

Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.

N Engl J Med, 2021 Jun 23

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Clin Cancer Res, 2021 Feb 23

Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.

European urology, 2023 Jul 05

Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).

The Journal of urology, 2023 Apr 26

Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).

Related Topics in Radiation Oncology